MetaCap

Benitec Biopharma Inc. (BNTC)

NASDAQ: BNTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.92-0.225 (-2.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BNTC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$285.88M
EPS (TTM)
-$1.02
Ex-dividend date
Jun 1, 2018
52-week range
7.72 – 14.39
Day range
7.75 – 8.16
Volume / Avg
268.68K / 174.01K
Beta
—

52-week range

$7.72$14.39

BNTC stock today

Shares of Benitec Biopharma (BNTC) finished lower on Nov 20 at $7.92, a drop of 2.76% or $0.225 per share, versus the S&P 500's 3.70% decline. Shares are 45.0% below their 52-week high of $14.39, set on Dec 31, 2025 and 2.5% above the 52-week low of $7.72, near the bottom of the past year's range. BNTC is down 41.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.3%.

Benitec Biopharma has posted a net loss over the last twelve months (EPS of -$1.02), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Benitec Biopharma

Company profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Headquarters
Hayward, CA
Employees
24
IPO year
2015

Financial highlights

Full financials

Benitec Biopharma reported a net loss of $45.5 million, compared with a loss of $37.9 million a year earlier. Diluted earnings per share came in at -$0.98.

Benitec Biopharma annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue——$0$75.00K$73.00K
Growth——-100.00%+2.74%+23.73%
Net income$-45.55M$-37.92M$-21.75M$-19.56M$-18.21M
EPS (diluted)$-0.98$-1.05$-1.22$-14.12$-37.88

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$23.75+200.06%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.26 vs $-0.30
Surprise
+13.33%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.765
Ex-dividend date
Jun 1, 2018

BNTC news

All BNTC news

Benitec Biopharma peers

Health Care sector
BNTC peer companies
CompanyPrice% ChgMarket capCompare
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs BNTC
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs BNTC
EVMNEvommune Inc.7.04-2.76%$291.10Mvs BNTC
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs BNTC
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs BNTC
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs BNTC
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs BNTC
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs BNTC

Indexes, lists and sector

Benitec Biopharma stock FAQ

What is Benitec Biopharma's stock price today?

BNTC last traded at $7.92 as of Nov 20, 4:00 PM EST, down 2.76% on the day. Prices are delayed at least 15 minutes.

Does Benitec Biopharma pay a dividend?

Yes. Benitec Biopharma pays $0.00 per share annually. The most recent dividend of $0.765 had an ex-dividend date of Jun 1, 2018.

Who is Benitec Biopharma's CEO?

Dr. Jerel A. Banks M.D., Ph.D. is the chief executive officer of Benitec Biopharma Inc., which has about 24 employees.

Has BNTC ever split its stock?

Yes. The most recent BNTC stock split was a 1-for-17 split on Jul 26, 2023, one of 4 splits on record.

What is the BNTC 52-week high?

The 52-week high for BNTC is $14.39 and the 52-week low is $7.72. The stock is currently 45.0% below its high.

Compare BNTC